GENEVA — Efforts to expand access to HIV prevention have received a major boost after the United States Food and Drug Administration (FDA) granted tentative approval to the first generic version of lenacapavir, a long-acting injection that can prevent HIV infection with just two doses a year.
The generic medication, developed by India’s Dr. Reddy’s Laboratories, is expected to cost approximately $40 per person annually in 120 eligible low- and middle-income countries. The development could make one of the most promising HIV prevention options more affordable for millions of people, particularly in countries where the cost of newer medicines has limited access.
The announcement was made on November 2, 2026, by the manufacturer and international health organizations that supported the development and regulatory approval of the generic drug. Initial supplies are expected to reach some countries before the end of 2026, with wider availability anticipated in 2027.
A Major Step Towards Affordable HIV Prevention
Lenacapavir is a long-acting antiretroviral medication used as pre-exposure prophylaxis (PrEP). Unlike traditional oral PrEP, which requires people to take a preventive pill every day, lenacapavir is administered through an injection twice a year.
The treatment offers an alternative for people who find it difficult to maintain a daily medication routine because of stigma, personal circumstances or limited access to healthcare services.
Until now, Gilead Sciences, the original developer of lenacapavir, was the sole supplier of the drug. Its branded version has been approved for HIV prevention, but the cost and limited supply have presented challenges for countries seeking to introduce it on a wider scale.
The generic version is expected to be available at a price comparable to existing daily oral prevention medication, potentially making the twice-yearly option more accessible.
How the $40 Generic Version Became Possible
The development involved collaboration between Dr. Reddy’s Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI) and the Wits Reproductive Health and HIV Institute (Wits RHI).
The organizations provided financial, technical and regulatory support to accelerate the development of an affordable generic formulation.
The FDA’s tentative approval came just 16 months after the original lenacapavir product received approval for HIV prevention in June 2025.
Tentative approval is a regulatory designation used for generic medicines while the original product remains protected by patent. It confirms that the generic meets the FDA’s relevant quality, safety and effectiveness requirements for the intended approval pathway, while allowing procurement for eligible international programs.
The arrangement is supported by voluntary licensing agreements that Gilead established with generic manufacturers. The licensing framework covers 120 low- and middle-income countries across parts of Africa, Asia and Latin America.
African Countries Could Benefit From Wider Access
The development is particularly significant for African countries, where HIV prevention remains a major public health priority.
According to the organizations supporting the generic launch, more than 125,000 people across 10 early-adopter African countries had already started using Gilead’s original lenacapavir before the generic version became available.
The lower expected price could help governments and health organizations expand access to the medication, particularly among populations that face barriers to existing prevention services.
For countries such as Nigeria, wider access to affordable prevention options could support efforts to reduce new infections. However, actual availability will depend on country-level regulatory approvals, procurement arrangements, funding and healthcare delivery capacity.
International health organizations have also emphasized that affordable medicine alone will not guarantee widespread access. Countries will need trained healthcare workers, reliable supply chains, appropriate testing services and community engagement to support successful implementation.
Important Considerations for Patients
Although lenacapavir offers a major advance in HIV prevention, it is not an HIV vaccine or a treatment for people already living with the virus. It is intended for HIV-negative individuals who need protection against infection.
People must undergo HIV testing before starting the medication and before subsequent injections. This is important because administering the drug to someone with an undiagnosed HIV infection could contribute to the development of drug resistance.
The World Health Organization recommended twice-yearly injectable lenacapavir as an additional PrEP option in July 2025, recognizing its potential to expand prevention choices for people at risk of HIV.
Global Rollout Expected to Expand in 2027
The FDA’s tentative approval represents an important step towards increasing the supply of affordable lenacapavir. However, the next challenge will be ensuring that eligible countries can obtain the medication and make it available to the people who need it.
The Global Fund has been working with governments and health partners to prepare for wider access as additional generic supplies become available. Its plans include expanding procurement options and supporting countries as they introduce the medication into their HIV prevention programs.
With the generic injection expected to cost about $40 annually, health advocates hope the development will reduce financial barriers and give more people access to convenient, long-acting HIV prevention.
The success of the rollout will ultimately depend on affordability, reliable supply, national approvals and the ability of healthcare systems to reach vulnerable communities.
Swifteradio.com
